Tripos Establishes Benchware Pantheon Partnership Program For Developers of Software Tools

Powerful and Flexible Benchware Pantheon Platform Enables Easy and Rapid Software Integration and Development

ST. LOUIS–Tripos™, a leading provider of drug discovery informatics products and services, today announced the creation of a worldwide Benchware® Pantheon™ Partner Program for software developers. The new program will allow third party developers to have direct access to the popular Benchware Pantheon code, opening the way for them to quickly and easily integrate their software tools and solutions into the robust platform.

Benchware Pantheon is a new software solution that enables discovery scientists to rapidly and accurately merge data from multiple sources, and then analyze and visualize that data for faster and better decision making. Researchers can integrate and translate various spreadsheets, merge biological data with chemical structures, and then use a range of tools to sort, analyze and visualize data in 2D and 3D. According to Tripos’ Chief Operating Officer, Patrick Flanagan, “This partnership effort gives creative software developers the perfect environment to combine the inherent power in Benchware Pantheon with their own unique solutions, providing their customers with significant added value.”

Brian Masek, Ph.D., Tripos’ Product Manager and Senior Scientist, says, “Developers understand the potential of Benchware Pantheon and what makes it so unique. The combination of a chemically aware spreadsheet and ‘grid view,’ with powerful 3D molecular visualization, makes it ideal for industry-standard plug-ins. The Pantheon interface allows developers to add their special applications to a universal, extensible platform that accommodates a variety of workflows.”

Developers interested in joining the partnership program are asked to contact Brian Masek for more information and qualification requirements.

About Tripos

Tripos, a Certara™ Company, is a global leader in innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Established in 1979, Tripos was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical and food design industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds that have the potential to become marketed drugs, foods, flavorings and fragrances. Headquartered in St. Louis, Missouri, Tripos serves more than 1,000 customers spanning over 46 countries.

About Certara

Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos (www.tripos.com) and Pharsight Corporation (www.pharsight.com). Tripos provides innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Pharsight provides software and scientific services to improve productivity and decision-making in clinical drug development. Certara focuses on reducing the barriers between the phases of research to speed discoveries in chemistry, and enabling pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.